• Understand how changes in health insurance will affect the pharmaceutical industry
• How will FDA regulatory change impact marketing and product forecasting
• How are your competitors accounting for healthcare reform in their forecast models? Benchmark your strategy

Kim Slocum, President, KDS Consulting

• How to build treatment simulations from disease specific epidemiology
• Understand how to incorporate therapy costs into simulations
• Learn to use health outcome data to further improve simulation accuracy
• Demonstrate demand on treatment infrastructure

Kirk Solo, Principal, Lexidyne LLC

• Understand the business benefits from creating and using integrated forecasts
• Learn how to automate processes and increase productivity
• Get insight into Shire case study and see how to implement integrated forecasts

Paul Minshull, President, Scarsin
Rob Lutz, Vice President of Business Analysis and Forecasting, Shire Pharmaceuticals

• Beat internal politics to set reasonable stakeholder expectations
• Learn from multiple case studies: how to overcome constrained resources to still deliver effective results and achieve excellence

Judith Kulich, Principal, ZS Associates
Nisha Gilra, Principal, ZS Associates

• How to forecast for the use of extended dosing or additional indications to extend life cycle
• How to build payer & patient reaction to additional indications into your value proposition
• Understand and utilize your forecasts in the context of a changing payer environment

William Berry, Senior Director of Sales Forecasting, Sanofi-Aventis

• Learn why we need to move away from point estimate forecasting in order to enable better strategic decision-making
• Discover how simulation-based modeling can help address the multi-level complexities of forecasting our evolving product portfolios

Michael Devinoff, Executive Director, Forecasting, Epidemiology and Predictive Analytics, Bristol-Myers Squibb

• The inevitability of human error and how it predicts problems for typical pharma forecasts
• The most common types of error in pharma forecasts
• Good practice for reducing errors
• Technological solutions for reducing errors

Gary Johnson, Founder, Inpharmation

• Understand how to build a structured framework for discounting peak preference share in quantitative market research.
• Get insight into the merits and flaws of correcting overstatement through qualitative judgment
• Beyond “Rule of Thumb”: learn innovative approaches to improve accuracy
• Case study: get a practical step-wise proposal for discounting peak preference share

Atul Saxena, Global Associate Director-Forecasting & Analytics, UCB

• Understand how to assess the competitive landscape for pipeline products, new indications or lifecycle extensions
• Learn how to adjust estimates to achieve more accurate, realistic predictions in a competitive space

Eric Chown, Assistant Director, Market Intelligence Oncology, Astellas Pharma

• Hear why forecasting has evolved and learn to understand your patient base
• How to move beyond scenario and towards patient based modeling as a standard in global and domestic forecasting

Anthony Pugliese, Associate Director, Launch Forecasting, Bristol-Myers Squib

• In recent years, we’ve witnessed launches that span the gamut from the fastest uptakes ever to slow-and-steady.
• How can you determine what your launch will look like, in order to set appropriate expectations and avoid overpromising/under delivering in the critical months post-launch?
• Consideration must be given to the 4P’s: the product profile, prescriber motivation, patient churn and payer access. Each must be examined and incorporated appropriately
• Accuracy in forecasting new product uptakes has major implications for investors, management, resourcing (sales and marketing), manufacturing and many other internal groups

Leslie Sandberg Orne, Partner, Trinity Partners

• How to use different analogs to develop and monitor launched products
• How to gauge performance success during the first 12 months of a product launch
• Understand how to forecast pipelines and why this is critical to investors and pharma
• What are the different data types and analyses required to triangulate new product forecasts? The best metrics to use to assess accuracy

Jerry Rosenblatt & Thomas Foster, Foster Rosenblatt
Leo MacDonald, Director, Global Strategic Analytics, Janssen
Matthew Rizzo, Managing Director, Orbimed Advisors
Andrew Berens, Senior Analyst, Bloomberg

• How to manage internal expectations and implement internal management culture change
• Learn to convey requirements and importance of innovating forecasting techniques to leadership
• How to manage expectations on frequency of forecasting, speed of delivery and deliver bad news

Spiro Gavaris, Director of Strategic Marketing, West-Ward Pharma

• Master the essentials and move towards excellence
• Lilly case study: build a sound process and achieve results
• Create rigorous, effective, timely and actionable forecasts

Justine Trinidad, VP, Nielsen BASES Pharmaceutical Practice
Robert Draper, Sr. Advisor, Global Forecasting, Lilly

• Create from analogues market penetration/uptake to increase new product forecast accuracy
• Integrate launch seasonality, future events and achieve transparency with post-launch assumptions
• How to build a patient-based baseline

Robert Carbone, President & CEO, Futurion
Olivier Benrubi, VP, Futurion

• Understand the key needs of forecasting Stakeholders
• Learn to create and communicate a digestible forecast with transparent assumptions
• Communicate base case forecast and key uncertainties and forecasting variability
• How to make clear, concise, and impactful presentations to executives

Zhen Tang, Director, Industry Insights, Bristol Myers-Squibb

• Learn to address asymmetry of information between originators and licensees
• How to address conflicting incentives for Business Development vs. internal portfolio management
• Understand the role of external analysts opinion in your BD evaluation
• Integration vs. isolation: what is the ideal organization of functions to ensure successful BD?

Suraj Moorthy, Senior Expert Strategy & Portfolio Management, Sanofi-Aventis

• Learn how to adapt forecasting methods for rare disease states
• How to overcome limited epidemiology data and forecast for small patient populations
• Get insight into effective alternatives to trend-based forecasting

Jeanne Penn, Director, Global Market Insights, Genzyme